Skip to main content
SpringerLink
Log in

Sertindole, a useful option in the treatment of schizophrenia, is not associated with an excess of overall mortality

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Murdoch D, Keating GM. Sertindole: a review of its use in schizophrenia. CNS Drugs 2006; 20(3): 233–55

    Article  PubMed  CAS  Google Scholar 

  2. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: a signal not confirmed. Int J Psychiatry Clin Pract 2002; 6Suppl. 1: S3–9

    Article  CAS  Google Scholar 

  3. Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs 2004; 18Suppl. 2: 19–30

    Article  PubMed  CAS  Google Scholar 

  4. H. Lundbeck A/S. Sertindole: summary of product characteristics. Copenhagen: H. Lundbeck A/S, 2005 Sep

    Google Scholar 

  5. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996 Mar; 124(1–2): 168–75

    Article  Google Scholar 

  6. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997 Jun; 154(6): 782–91

    PubMed  CAS  Google Scholar 

  7. Hale A, Azorin J-M, Kasper S, et al. Sertindole improves both the positive and negative symptoms of schizophrenia: results of a phase III trial. Int J Psychiatry Clin Pract 2000 Mar; 4: 55–62

    Article  CAS  Google Scholar 

  8. Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol Bull 1998; 34(1): 61–9

    PubMed  CAS  Google Scholar 

  9. Kane J, Potkin S, Buckley P, et al. Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia [abstract and poster]. 10th International Congress on Schizophrenia Research; 2005 Apr 2–6; Savannah (GA)

  10. Azorin J-M, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int Clin Psychopharmacol 2006 Jan; 21(1): 49–56

    Article  PubMed  Google Scholar 

  11. Haverkamp W, Eckardt L, Matz J. Sertindole: cardiac electrophysiological profile. Int J Psychiatry Clin Pract 2002; 6Suppl. 1: S11–20

    Article  CAS  Google Scholar 

  12. Kasper S, Toumi M. The clinical safety and tolerability profile of sertindole [abstract no. S422]. Int J Neuropsychopharmacol 2004 Jun; 7Suppl. 1: S422 plus poster presented at the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 Jun 20–24; Paris

    Google Scholar 

  13. Lindström E, Farde L, Eberhard J, et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 2005; 8: 615–29

    Article  PubMed  Google Scholar 

  14. Sturkenboom MCJM, Picelli G, Moore N. Mortality during use of sertindole and other anti-psychotics: a comparative cohort study [poster]. 9th International Congress on Schizophrenia Research; 2003 Mar 29–Apr 2; Colorado Springs (CO)

  15. Kasper S, Möller H-J, Hale A. The European Post-marketing Observational Serdolect (EPOS) study: an investigation of the safety of antipsychotic drug treatment. Copenhagen: H. Lundbeck A/S, 2006. (Data on file)

    Google Scholar 

  16. Peuskens J, Moore N, Azorin J-M, et al. Sertindole safety and exposure: a retrospective study on 8, 608 patients in Europe [poster]. 9th International Congress on Schizophrenia Research; 2003 Mar 29–Apr 2; Colorado Springs (CO)

  17. Toumi M, Mann R, Hall G, et al. Mortality associated with sertindole: review of epidemiological studies [abstract no. NR560 plus poster]. American Psychiatric Association 2003 Annual Meeting; 2003 May 17–22; San Francisco (CA)

  18. European Agency for the Evaluation of Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products [online]. Available from URL: http://www.emea.eu.int [Accessed 2006 Jul 27]

  19. Wilton LV, Heeley EL, Pickering RM, et al. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol (Oxf) 2001; 15(2): 120–6

    Article  CAS  Google Scholar 

  20. Toumi M, Auquier P, François C. Sertindole safety and tolerability in a patient named use programme [poster]. 9th International Congress on Schizophrenia Research; 2003 Mar 29–Apr 2; Colorado Springs (CO)

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sertindole, a useful option in the treatment of schizophrenia, is not associated with an excess of overall mortality. Drugs Ther. Perspect 22, 1–4 (2006). https://doi.org/10.2165/00042310-200622120-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622120-00001

Search

Navigation